ReviewCell communication and signaling : CCS2026
Integrins in cancer: insights into mechanisms and therapeutic potential.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- High-Density Type I Collagen Promotes IFN-γAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026Review
- Injectable bioactive hydrogels as pharmacological drug delivery platforms for post-myocardial infarction cardiac repair: therapeutic cargo engineering, stimuli-responsive release mechanisms, and translational perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrins are transmembrane glycoproteins that act as essential adhesion receptors, allowing cells to communicate with the extracellular matrix (ECM). This interaction not only helps cells regulate adhesion, but also transmits signals that guide a variety of cellular processes. Once bound to the ECM, integrins play an important role in the cell differentiation, migration, proliferation, and survival, thereby maintaining tissue homeostasis. However, when integrin signaling becomes dysregulated, it is often associated with tumor development and progression. Abnormal integrin activity promotes uncontrolled cell growth, resistance to apoptosis, and the promotion of angiogenesis in tumors. They also provide resistance to therapies by disrupting growth suppressors. Due to their documented role in the process of tumorigenesis, integrins have become an interesting target for anticancer therapy. In this review, we discuss the function and structure of integrins, emphasizing how altered signaling in integrins consequently leads to cancer formation, progression, and metastasis. In addition, we review existing therapies that target integrins, discuss their limitations, and look at the future of integrin-based therapies. This review deepens our understanding of integrins, their role in cancer, and their possible role as a cancer biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.